Charles River Laboratories to acquire MPI Research for $800m
In a strategic move to bolster its position in the pharmaceutical research sector, Charles River Laboratories International, Inc. has agreed to acquire Michigan-based non-clinical contract ... Read More
Cyclacel Pharmaceuticals’ sapacitabine fails to meet primary endpoint in Phase 3 blood cancer trial
Cyclacel Pharmaceuticals, a New Jersey-based biopharmaceutical company, announced that its experimental blood cancer drug, sapacitabine (CYC682), did not meet the primary endpoint in the pivotal ... Read More